References
- DSM-V. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, fifth edition, 2013.
- Hodgkins P, Shaw M, Coghill D, Hechtman L. Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry 2012; 21:477–492.
- McDonagh MS, Peterson K, Thakurta S, Low A. Drug class review: pharmacologic treatments for attention deficit hyperactivity disorder: final update 4 report [Internet]. Drug Class Reviews 2011.
- Hannestad J, Gallezot JD, Planeta-Wilson B, Lin SF, Williams WA, van Dyck CH, et al. Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry 2010; 68:854–860.
- Volkow ND, Fowler JS, Wang GJ, Ding YS, Gatley SJ. Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Eur Neuropsychopharmacol 2002; 12:557–566.
- Chai G, Governale L, McMahon AW, Trinidad JP, Staffa J, Murphy D. Trends of outpatient prescription drug utilization in US children, 2002–2010. Pediatrics 2012; 130:23–31.
- SFK. Stichting Farmaceutische Kengetallen. Explosieve groei ADHD-middelen zet door. Pharmaceutisch Weekblad 2008; 143:29–30.
- SFK. Stichting Farmaceutische Kengetallen. Gebruik ADHD-middelen niet in te tomen. Pharmaceutisch Weekblad 2012; 147:30–31.
- Levine M, Froberg B, Ruha AM, Burns-Ewald M, Yen M, Claudius IA, et al. Assessing the toxicity and associated costs among pediatric patients admitted with unintentional poisonings of attention-deficit/hyperactivity disorder drugs in the United States. Clin Toxicol (Phila) 2013; 51:147–150.
- Bogle KE, Smith BH. Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences. Curr Drug Abuse Rev 2009; 2:157–176.
- Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Dart RC. 2010 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol (Phila) 2011; 49:910–941.
- Foley R, Mrvos R, Krenzelok EP. A profile of methylphenidate exposures. J Toxicol Clin Toxicol 2000; 38:625–630.
- Klein-Schwartz W. Pediatric methylphenidate exposures: 7-year experience of poison centers in the United States. Clin Pediatr (Phila) 2003; 42:159–164.
- White SR, Yadao CM. Characterization of methylphenidate exposures reported to a regional poison control center. Arch Pediatr Adolesc Med 2000; 154:1199–1203.
- Spiller HA, Hays HL, Aleguas A Jr. Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. CNS Drugs 2013; 27:531–543.
- Scharman EJ, Erdman AR, Cobaugh DJ, Olson KR, Woolf AD, Caravati EM, et al. Methylphenidate poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2007; 45:737–752.
- US Food and Drug administration (FDA). Maximum Recommended Therapeutic Dose (MRTD) Database, 2013.
- Klein-Schwartz W, McGrath J. Poison centers’ experience with methylphenidate abuse in pre-teens and adolescents. J Am Acad Child Adolesc Psychiatry 2003; 42:288–294.
- American Heart Association. 2013. http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/AboutHighBlood Pressure/About-High-Blood-Pressure_UCM_002050_Article.jsp, consulted January 2013.
- Derksen-Lubsen G. Compendium Kindergeneeskunde - Diagnostiek en Behandeling. 2011, 4th ed. Houten: Bohn Stafleu van Loghum.
- El-Radhi AS, Barry W. Thermometry in paediatric practice. Arch Dis Child 2006; 91:351–356.
- Hunter J, Rawlings-Anderson K. Respiratory assessment. Nurs Stand 2008; 22:41–43.
- Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995; 311:376–380.
- Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33:159–174.
- Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17: 857–872.
- Backman E, Sjoberg G. Methylphenidate overdose in adolescents and adults - experience in Sweden (Abstract EAPCCT XXVII International Congress). Clin Toxicol (Phila) 2007; 45(:366.
- Bailey B, Letarte A, Abran MC. Methylphenidate unintentional ingestion in preschool children. Ther Drug Monit 2005; 27:284–286.
- Koller M, Schnorf-Huber S, Kupferschmidt H, Meier-Abt P. Acute toxicity of oral methylphenidate (MP) overdose in Switzerland (Abstract EAPCCT XXII International Congress). Clin Toxicol (Phila) 2002; 40:276.
- Marquadt K, Alsop J, Lamb JP, Lai C, Walsh M, Albertson TE. Methylphenidate ingestions: comparison of drug formulations (Abstract NACCT Annual Meeting). Clin Toxicol (Phila) 2004; 42:728.
- Trip AM, Visser ST, Kalverdijk LJ, de Jong-van den Berg LT. Large increase of the use of psycho-stimulants among youth in the Netherlands between 1996 and 2006. Br J Clin Pharmacol 2009; 67:466–468.
- SFK. Data obtained from a 2013 data request to SFK. Stichting Farmaceutische Kengetallen 2013.
- Levine B, Caplan YH, Kauffman G. Fatality resulting from methylphenidate overdose. J Anal Toxicol 1986; 10:209–210.
- Massello W III, Carpenter DA. A fatality due to the intranasal abuse of methylphenidate (Ritalin). J Forensic Sci 1999; 44:220–221.
- Cantrell FL, Ogera P, Mallett P, McIntyre IM. Fatal oral methylphenidate intoxication with postmortem concentrations. J Forensic Sci 2014; 59:847–849.